Welcome to AiCuris: The Powerhouse for Anti-Infectives
AiCuris (from 'Anti-infective Cures') is a pharmaceutical company focused exclusively on the discovery, research and development of novel antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases.
Founded in 2006 from Bayer's virology and bacteriology research divisions, AiCuris today has an innovative pipeline of novel anti-infectives and a team of internationally regarded scientists and drug developers. With its tight focus on specialist markets with high medical need, the company is perfectly positioned for growth and success.
Pritelivir Clinical Phase 2 Study
AiCuris Initiates U.S. Clinical Phase 2 Trial with Oral Pritelivir for the Treatment of HSV Infections in Immunocompromised Adults
Opening of the first site in its clinical phase 2 study, PRIOH-1, to evaluate the efficacy and safety of oral pritelivir.
Pritelivir Phase 2 Publication in JAMA
AiCuris Announces Publication of Phase 2 Clinical Trial Results of Investigational Anti-Herpes Simplex Virus Agent Pritelivir in JAMA
Study results clearly supported pritelivir to be more effective than valacyclovir for suppression of herpes simplex virus (HSV) genital shedding in patients with frequent recurrences.
Antibiotic AIC499: Phase 1 started
AiCuris Initiates Clinical Development of AIC499, a Novel Resistance-Breaking Antibiotic against a Broad Range of MDR Gram-Negative Bacteria
Program supported by the Innovative Medicines Initiative